Skip to main content

Advertisement

Table 3 Safety summary (randomized population)

From: Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

 DM-DYSLIPIDEMIADM-INSULIN
Alirocumab (n = 95)UC (n = 47)Alirocumab (n = 118)Placebo (n = 57)
TEAEs occurring in ≥ 2% of individuals by preferred term, n (%)
 Urinary tract infection5 (5.3)2 (4.3)3 (2.5)4 (7.0)
 Diarrhea5 (5.3)3 (6.4)3 (2.5)3 (5.3)
 Hypertension3 (3.2)1 (2.1)5 (4.2)3 (5.3)
 Influenza3 (3.2)3 (6.4)4 (3.4)1 (1.8)
 Musculoskeletal pain4 (4.2)1 (2.1)3 (2.5)2 (3.5)
 Back pain2 (2.1)2 (4.3)4 (3.4)0
 Dizziness3 (3.2)1 (2.1)3 (2.5)2 (3.5)
 Fatigue2 (2.1)2 (4.3)3 (2.5)1 (1.8)
 Cataract1 (1.1)1 (2.1)4 (3.4)0
 Myalgia2 (2.1)1 (2.1)3 (2.5)0
 Nausea2 (2.1)1 (2.1)2 (1.7)2 (3.5)
 Pain in extremity2 (2.1)2 (4.3)2 (1.7)1 (1.8)
 Bronchitis02 (4.3)3 (2.5)1 (1.8)